(S)-CR8 | CAS#1084893-56-0 | CDK inhibitor

MedKoo Cat#: 562570 | Name: (S)-CR8

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

(S)-CR8 is a potent second-generation cyclin-dependent kinase (CDK) inhibitor. It acts by limiting microglial activation, astrocytosis, neuronal loss, and neurologic dysfunction after experimental traumatic brain injury.

Chemical Structure

(S)-CR8

CAS#1084893-56-0

Theoretical Analysis

MedKoo Cat#: 562570

Name: (S)-CR8

CAS#: 1084893-56-0

Chemical Formula: C24H29N7O

Exact Mass: 431.2434

Molecular Weight: 431.54

Elemental Analysis: C, 66.80; H, 6.77; N, 22.72; O, 3.71

Price and Availability

Size	Price	Availability	Quantity
5mg	USD 375.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

(S)-CR8; (S) CR8; (S)CR8;

IUPAC/Chemical Name

(S)-2-((9-isopropyl-6-(methyl(4-(pyridin-2-yl)phenyl)amino)-9H-purin-2-yl)amino)butan-1-ol

InChi Key

ULEOUNVVBPZETL-SFHVURJKSA-N

InChi Code

InChI=1S/C24H29N7O/c1-5-18(14-32)27-24-28-22(21-23(29-24)31(15-26-21)16(2)3)30(4)19-11-9-17(10-12-19)20-8-6-7-13-25-20/h6-13,15-16,18,32H,5,14H2,1-4H3,(H,27,28,29)/t18-/m0/s1

SMILES Code

CC[C@H](NC1=NC(N(C2=CC=C(C3=NC=CC=C3)C=C2)C)=C4N=CN(C(C)C)C4=N1)CO

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 431.54 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Goulding SP, de Guglielmo G, Carrette LLG, George O, Contet C. Systemic Administration of the Cyclin-Dependent Kinase Inhibitor (S)-CR8 Selectively Reduces Escalated Ethanol Intake in Dependent Rats. Alcohol Clin Exp Res. 2019 Oct;43(10):2079-2089. doi: 10.1111/acer.14177. Epub 2019 Aug 30. PMID: 31403700; PMCID: PMC6779498. 2: Billot K, Coquil C, Villiers B, Josselin-Foll B, Desban N, Delehouzé C, Oumata N, Le Meur Y, Boletta A, Weimbs T, Grosch M, Witzgall R, Saunier S, Fischer E, Pontoglio M, Fautrel A, Mrug M, Wallace D, Tran PV, Trudel M, Bukanov N, Ibraghimov-Beskrovnaya O, Meijer L. Casein kinase 1ε and 1α as novel players in polycystic kidney disease and mechanistic targets for (R)-roscovitine and (S)-CR8. Am J Physiol Renal Physiol. 2018 Jul 1;315(1):F57-F73. doi: 10.1152/ajprenal.00489.2017. Epub 2018 Mar 14. PMID: 29537311; PMCID: PMC6087785. 3: Bukanov NO, Moreno SE, Natoli TA, Rogers KA, Smith LA, Ledbetter SR, Oumata N, Galons H, Meijer L, Ibraghimov-Beskrovnaya O. CDK inhibitors R-roscovitine and S-CR8 effectively block renal and hepatic cystogenesis in an orthologous model of ADPKD. Cell Cycle. 2012 Nov 1;11(21):4040-6. doi: 10.4161/cc.22375. Epub 2012 Oct 3. PMID: 23032260; PMCID: PMC3507499. 4: Delehouzé C, Godl K, Loaëc N, Bruyère C, Desban N, Oumata N, Galons H, Roumeliotis TI, Giannopoulou EG, Grenet J, Twitchell D, Lahti J, Mouchet N, Galibert MD, Garbis SD, Meijer L. CDK/CK1 inhibitors roscovitine and CR8 downregulate amplified MYCN in neuroblastoma cells. Oncogene. 2014 Dec 11;33(50):5675-87. doi: 10.1038/onc.2013.513. Epub 2013 Dec 9. PMID: 24317512; PMCID: PMC4087096. 5: Troadec S, Blairvacq M, Oumata N, Galons H, Meijer L, Berthou C. Antitumoral effects of cyclin-dependent kinases inhibitors CR8 and MR4 on chronic myeloid leukemia cell lines. J Biomed Sci. 2015 Jul 17;22(1):57. doi: 10.1186/s12929-015-0163-x. PMID: 26184865; PMCID: PMC4504225. 6: Ramadori P, Woitok MM, Estévez-Vázquez O, Benedé-Ubieto R, Leal-Lassalle H, Lamas-Paz A, Guo F, Fabre J, Otto J, Verwaayen A, Reissing J, Bruns T, Erschfeld S, Haas U, Paffen D, Nelson LJ, Vaquero J, Bañares R, Trautwein C, Cubero FJ, Liedtke C, Nevzorova YA. Lack of Cyclin E1 in hepatocytes aggravates ethanol- induced liver injury and hepatic steatosis in experimental murine model of acute and chronic alcohol-associated liver disease. Biochim Biophys Acta Mol Basis Dis. 2023 Apr;1869(4):166646. doi: 10.1016/j.bbadis.2023.166646. Epub 2023 Feb 1. PMID: 36736843. 7: Norez C, Vandebrouck C, Bertrand J, Noel S, Durieu E, Oumata N, Galons H, Antigny F, Chatelier A, Bois P, Meijer L, Becq F. Roscovitine is a proteostasis regulator that corrects the trafficking defect of F508del-CFTR by a CDK- independent mechanism. Br J Pharmacol. 2014 Nov;171(21):4831-49. doi: 10.1111/bph.12859. PMID: 25065395; PMCID: PMC4294108. 8: Husson H, Moreno S, Smith LA, Smith MM, Russo RJ, Pitstick R, Sergeev M, Ledbetter SR, Bukanov NO, Lane M, Zhang K, Billot K, Carlson G, Shah J, Meijer L, Beier DR, Ibraghimov-Beskrovnaya O. Reduction of ciliary length through pharmacologic or genetic inhibition of CDK5 attenuates polycystic kidney disease in a model of nephronophthisis. Hum Mol Genet. 2016 Jun 1;25(11):2245-2255. doi: 10.1093/hmg/ddw093. Epub 2016 Apr 5. PMID: 27053712; PMCID: PMC5081056.